How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,000 results for

Rheumatoid Arthritis Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Rheumatoid arthritis in adults: management

Rheumatoid arthritis in adults: management Rheumatoid arthritis in adults: Rheumatoid arthritis in adults: management management NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng100 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Rheumatoid arthritis in adults: management (NG100) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 31Contents Contents Overview 5 Who is it for? 5

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts

The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts To examine associations between BMI and disease activity, functional ability and quality of life in RA.Data from two consecutive, similarly designed UK multicentre RA inception cohorts were used: the Early RA Study (ERAS) and the Early RA Network (ERAN). Recruitment figures (...) was associated with higher DAS28 scores at year 2, but not at year 5, and also associated with significantly higher HAQ and SF-36 PCS scores at years 2 and 5.Obesity prevalence is rising in early RA and associates with worse disease activity, function and health-related quality of life, with a significant negative impact on achieving a low DAS28. The data argue strongly for obesity management to become central to treatment strategies in RA.

2018 EvidenceUpdates

4. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

option for severe rheumatoid arthritis that does not respond to conventional therapy. Therapeutic monitoring of TNF-alpha inhibitors could help to optimise their use, improving management of the condition and outcomes that are important for people with rheumatoid arthritis. These include how long their disease is in remission, the rate of flares and relapse, and health-related quality of life. The clinical-effectiveness evidence for ELISA tests for therapeutic monitoring of TNF-alpha inhibitors (...) person to person, but often results in substantial morbidity, impaired physical activity, poor quality of life, and reduced life expectancy. It is marked by relapses (when the disease flares up) and remission (when there are few or no signs or symptoms). Rheumatoid arthritis is currently incurable, and people will remain on treatment for the rest of their lives. The care pathways 2.7 Initial diagnosis and management of rheumatoid arthritis, including monitoring of treatment response, are covered

2019 National Institute for Health and Clinical Excellence - Diagnostics Guidance

5. Drugs for the Management of Rheumatoid Arthritis

Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis | CADTH.ca Find the information you need Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis Published on: April 25, 2018 Project Number: HT0010-000 Product Line: Result type: Report Key Messages For rheumatoid arthritis patients with moderate to severe disease in whom treatment with methotrexate has failed or who are intolerant to methotrexate (...) PUBLISHED : April 2018 Health Technology Assessment Clinical Evaluation PUBLISHED : March 2018 Health Technology Assessment Clinical Evaluation - Appendices PUBLISHED : March 2018 Drugs for the management of rheumatoid arthritis: clinical evaluation – Project Protocol Health Technology Assessment Project Protocol PUBLISHED : June 2016 Health Technology Assessment PUBLISHED : May 2017 Health Technology Assessment PUBLISHED : September 2016 Health Technology Assessment PUBLISHED : September 2016 Related

2016 CADTH - Health Technology Assessment

6. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. (PubMed)

Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional treatment for pain might be required. Because comorbidity is highly prevalent in people with inflammatory arthritis (...) ). The study population comprised adults (>18 years) with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthritis who had gastrointestinal and/or hepatic comorbid conditions. Outcomes of interest were pain, adverse effects, function and quality of life. Studies that included a mixed population of inflammatory arthritis and other conditions were included only if results for inflammatory arthritis were reported separately.Two review authors independently selected trials

2012 Cochrane

7. Randomised controlled trial: Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities

Randomised controlled trial: Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) of rheumatoid arthritis and management of comorbidities Article Text Primary health care Randomised controlled trial Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities Mwidimi Ndosi Correspondence to : Dr Mwidimi Ndosi, University of Leeds, School of Healthcare, Baines Wing, Leeds LS2 9JT, UK; m.e.ndosi{at}leeds.ac.uk Statistics from Altmetric.com Commentary on : Dougados M , Soubrier M , Perrodeau E , et al . Impact

Full Text available with Trip Pro

2016 Evidence-Based Nursing

8. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). (PubMed)

Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Despite optimal therapy with disease-modifying antirheumatic drugs, many people with inflammatory arthritis (IA) continue to have persistent pain that may require additional therapy.To assess the benefits and safety of combination pain therapy for people with IA (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis

2011 Cochrane

9. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how (...) human monoclonal antibody produced in Chinese Hamster Ovary cells. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear to slightly opalescent, colourless to slightly yellowish solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Rheumatoid arthritis Hyrimoz in combination with methotrexate, is indicated for: • the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease

2018 European Medicines Agency - EPARs

10. Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 (...) of the Psoriasis Area and Severity Index (PASI) score PBMC Peripheral blood mononuclear cells PC Process characterisation PD Pharmacodynamics PETG Polyethylene tetraphthalate copolymer PFS Pre-filled syringe Ph. Eur. European Pharmacopoeia PK Pharmacokinetics PP Process parameters PPS Per-protocol analysis set PPso Plaque Psoriasis PsA Psoriatic Arthritis PsO; Ps Psoriasis p.v. Paravenous PV Process validation R2 adj Adjusted correlation coefficient RA Rheumatoid Arthritis RGA Reporter Gene Assay s.c

2018 European Medicines Agency - EPARs

11. Diagnosis and Management of Rheumatoid Arthritis: A Review. (PubMed)

Diagnosis and Management of Rheumatoid Arthritis: A Review. Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to severe joint damage and disability. Significant progress has been made over the past 2 decades regarding understanding of disease pathophysiology, optimal outcome measures, and effective treatment strategies, including the recognition of the importance of diagnosing and treating RA early.Early diagnosis and treatment of RA can avert or substantially slow

2018 JAMA

12. Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry (PubMed)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients

Full Text available with Trip Pro

2017 Rheumatology and therapy

13. Evaluation of Usability and Acceptance of a New Autoinjector Intended for Methotrexate Subcutaneous Self-Administration in the Management of Rheumatoid Arthritis (PubMed)

Evaluation of Usability and Acceptance of a New Autoinjector Intended for Methotrexate Subcutaneous Self-Administration in the Management of Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, for which the introduction of injectable treatments has had a major impact on quality of life directly related to the disease. The purpose of this descriptive study was to evaluate the usability of a new autoinjector, intended for methotrexate self-administration

Full Text available with Trip Pro

2017 Rheumatology and therapy

14. Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis (PubMed)

Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis Traditional and biologic disease-modifying antirheumatic drugs (DMARDs) are effective medications for the management of rheumatoid arthritis (RA). However, the effects of these medications on immune function raises concern that they may increase long-term cancer risk. The baseline risk for some cancers appears to differ in patients with RA compared to the general population, with the former having (...) of immunosuppressive medications. Overall, cancer risk in patients with RA is slightly above that of the general population, with the increased risk likely secondary to an increased risk of lymphomas in those with high disease activity. Risk mitigation includes management of RA disease activity as well as age- and sex-appropriate cancer screening.

Full Text available with Trip Pro

2017 Rheumatology and therapy

15. Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis (PubMed)

Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoid arthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients with RA. Subclinical CVD may be present since the early phase of RA. Not only traditional but also non-traditional CV risk factors are involved in the pathogenesis of RA-related CVD. Due (...) to the lack of specifically designed randomized clinical trials, it is still unclear which tools to use to perform CV risk assessment, how to interpret the results and which interventions are appropriate in RA patients both to prevent and to manage CVD. Based on the available evidence, we propose a practical approach.

Full Text available with Trip Pro

2017 Rheumatology and therapy

16. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis (PubMed)

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoid arthritis (RA). Development of pulmonary manifestations may be due to the systemic disease itself; to serious respiratory adverse events such as pneumonitis and infections secondary to therapy; or to lifestyle habits such as smoking. Rheumatologists often need to make important treatment (...) decisions and plan future care in RA patients with respiratory comorbidities, despite the absence of clear evidence or consensus. In this review we evaluate the clinical assessment and management of RA-associated interstitial lung disease, bronchiectasis, serious (including opportunistic) infection, and smoking-related diseases. We summarize the international recommendations for the management of such conditions where available, refer to published best practice on the basis of scientific literature

Full Text available with Trip Pro

2017 Rheumatology and therapy

17. A critical appraisal of clinical practice guidelines for the treatment or management of rheumatoid arthritis and osteoarthritis: systematic review and assessment using AGREE II

A critical appraisal of clinical practice guidelines for the treatment or management of rheumatoid arthritis and osteoarthritis: systematic review and assessment using AGREE II Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

18. The quantity and quality of complementary and alternative medicine recommendations in clinical practice guidelines for the treatment or management of rheumatoid arthritis and osteoarthritis: systematic review and assessment using AGREE II

The quantity and quality of complementary and alternative medicine recommendations in clinical practice guidelines for the treatment or management of rheumatoid arthritis and osteoarthritis: systematic review and assessment using AGREE II Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission

2019 PROSPERO

19. Role of diet in the management of rheumatoid arthritis: a systematic review

Role of diet in the management of rheumatoid arthritis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

20. How effective are systemic glucocorticoids for pain management in patients with rheumatoid arthritis? A systematic review

How effective are systemic glucocorticoids for pain management in patients with rheumatoid arthritis? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>